-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
ZyVersa Therapeutics, Inc. annual/quarterly Deferred State and Local Income Tax Expense (Benefit) history and growth rate from 2022 to 2024.
- ZyVersa Therapeutics, Inc. Deferred State and Local Income Tax Expense (Benefit) for the quarter ending December 31, 2022 was -$34.8K.
- ZyVersa Therapeutics, Inc. annual Deferred State and Local Income Tax Expense (Benefit) for 2024 was -$164K, a 96.3% increase from 2023.
- ZyVersa Therapeutics, Inc. annual Deferred State and Local Income Tax Expense (Benefit) for 2023 was -$4.47M, a 826% decline from 2022.
Deferred State and Local Income Tax Expense (Benefit), Annual (USD)
Deferred State and Local Income Tax Expense (Benefit), YoY Annual Growth (%)